Abstracts from the 5th International Porto Congress of Multiple Sclerosis
Keywords5th International Porto Congress Abstracts Multiple sclerosis
The studies referred to in the abstracts in this supplement may have been funded by sponsors, grants or institutions. The article processing charges for the publication of this supplement was funded by Roche. The supplement funder had no involvement in the writing or research, unless indicated for an abstract, and no involvement in the Scientific Committee's review procedure.
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for their abstracts, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Authors of abstracts may have relevant disclosures, which are not published here as this is a compilation of the abstracts only.
Compliance with Ethics Guidelines
The Supplement includes abstracts, not full original research articles, so that compliance with ethics is not reported. The Criteria for abstract selection were: Submitted abstracts were evaluated by at least 2 members of the scientific committee based on originality, the relevance of findings, the soundness of the content and the structural quality. The supplement was then peer reviewed by an Editorial Board Member of Neurology and Therapy, independent of the meeting’s abstract submission process.
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- 1.EPI002, Martins R, Albuquerque C. Quality of life of the person with multiple sclerosis. Encore abstract presented at the 3rd International Porto Congress of Multiple Sclerosis, Porto, Portugal, 27–28 February 2015. Sinapse, Volume 15, No.1, May 2015, p.165. Reproduced with permission.Google Scholar
- 2.EPI010, Schippling S, Sormani MP, De Stefano N, Giovannoni G, Galazka A, Keller B, Alexandri N. CLARITY: an analysis of severity and frequency of relapses in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets or placebo. Encore abstract presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Berlin, Germany, 10–12 October 2018. http://www.professionalabstracts.com/ectrims2018/iplanner/#/presentation/1088. © The Author(s).
- 3.EPI011, Giovannoni G, Montalban X, Rammohan K, Cook S, Comi G, Rieckmann P, Soelberg-Sorensen P, Vermersch P, Dangond F, King J, Roy S, Damian D. P28 efficacy of cladribine tablets in patients with highly active relapsing-remitting multiple sclerosis: analysis of pooled double-blind data from the CLARITY and ONWARD studies. Abstract presented at The Australian & New Zealand Association of Neurologists (ANZAN) 2018 ASM May 29-June 1, J Neurol Neurosurg Psychiatry 2018;89:A27-A28. Encore abstract presented at the Annual Congress 2018 of the Swiss Neurological Society, Vaud, Switzerland, Sep 27-28, Clinical & Translational Neuroscience 2018: 2(Supplement) 1S–34S. https://doi.org/10.1177/2514183X18802121 Reproduced with Permission.
- 4.EPII016, Cook S, Giovannoni G, Vermersch P, Soelberg-Sorensen P, Keller B, Jack D. Lymphopenia rates in CLARITY/CLARITY Extension are unrelated to disease activity at baseline. Encore abstract presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Berlin, Germany, 10–12 October 2018. http://www.professionalabstracts.com/ectrims2018/iplanner/#/presentation/1431. © The Author(s).
- 5.EPIII024, Sormani MP, Freedman MS, Aldridge J, Marhardt K, De Stefano N. Disease activity as assessed by the MAGNIMS score predicts long-term clinical disease activity (CDA)-free status and disability progression in patients treated with subcutaneous interferon beta-1a. Encore Abstract: 4th Congress of the European Academy of Neurology, Lisbon, Portugal, June 2018, EAN 2019 ePresentation Sessions. Eur J Neurol 25(2):277–573. https://doi.org/10.1111/ene.13700. Reproduced with permission.
- 6.EPIII029, Brandão Nascimento AC, Araujo e Araujo AR, Meneguette NS, Papais Alvarenga M, Vasconcelos CCF, Bento CAM, Rafful PP, Brandao LA, Papais Alvarenga RM. Magnetic resonance imaging findings at optic neuritis of recurrent opticspinal phenotype, multiple sclerosis in a cohort of Brazilian patients from Rio de Janeiro. Abstract accepted to be held at the European Congress of Radiology, Vienna, Austria, February 27–March 3, 2019. Insights into Imaging. 2019;10(Suppl 1):22 p.S301. https://insightsimaging.springeropen.com/track/pdf/10.1186/s13244-019-0713-y. © The Author(s).
- 7.EPIV034, das Neves SP, Serre-Miranda C, Nobrega C, Roque S, Cerqueira JJ, Correia-Neves M, Marques F. Immune thymic profile of the MOG-induced experimental autoimmune encephalomyelitis mouse model. Front Immunol. 2018;9:2335. 10.3389/ fimmu.2018.02335. https://www.frontiersin.org/articles/10.3389/fimmu.2018.02335/full? © The Author(s).
- 8.OP02, Gil A, et al. Pilot Study of Telemedicine in multiple sclerosis to evaluate the effectiveness of a telecommunication system for the detection of the clinical activity of the disease in the number of relapses with respect to the standard clinical practice. TELEM. E-poster presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Berlin, 10–12 October 2018. https://www.ectrims-congress.eu/2018/abstracts/eposters-only.html. © The Author(s).
- 9.OP03, Duarte S, et al. Coffee intake and multiple sclerosis disability. E-poster presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Berlin, 10–12 October 2018. https://www.ectrims-congress.eu/2018/abstracts/eposters-only.html. © The Author(s).